Scientists call the intermediate research results “very encouraging.” In the last phase of testing, up to 30 thousand volunteers will take part.
The German biopharmaceutical company CureVac NV has announced the successful completion of the second phase of the coronavirus vaccine trial and now plans to begin the final phase before the end of the year. This was reported by the press service of the company on Tuesday, November 3.
“We are ready to start a key test 2b / 3 (2nd-3rd phase) By the end of 2020,” it said.
Previously it became known that CureVac plans to begin a global clinical trial of 2b / 3 with almost 30 thousand volunteers in the fourth quarter of 2020.
The first phase of the trial was carried out on healthy adult volunteers in Germany and Belgium. The CVnCoV vaccine is currently in a phase 2a clinical trial in adults in Peru and Panama. Interim results from the study, in particular Phase 1, which covered more than 250 healthy people between the ages of 18 and 60, are “very encouraging,” said Professor Peter Kremsner, director of the Institute for Tropical Medicine at the University of Tubingen and lead investigator for Phase 1.
As noted in the company, the reactogenicity of the vaccine was constantly monitored by the Commission for Monitoring Data and Safety. The vaccine was generally well-tolerated at all doses tested, with no associated serious side effects.